دورية أكاديمية
Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease
| العنوان: | Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease |
|---|---|
| المؤلفون: | Wang, G, Li, Y, Xiong, C, Benzinger, TLS, Gordon, BA, Hassenstab, J, Aschenbrenner, AJ, McDade, E, Clifford, DB, Libre-Guerra, JJ, Shi, X, Mummery, CJ, van Dyck, CH, Lah, JJ, Honig, LS, Day, G, Ringman, JM, Brooks, WS, Fox, NC, Suzuki, K, Levin, J, Jucker, M, Delmar, P, Bittner, T, Bateman, RJ |
| المصدر: | Alzheimer's and Dementia (2024) (In press). |
| بيانات النشر: | Wiley |
| سنة النشر: | 2024 |
| المجموعة: | University College London: UCL Discovery |
| مصطلحات موضوعية: | Dominantly Inherited Alzheimer Network, autosomal dominant Alzheimer's disease, gantenerumab, latent class analysis, solanezumab, surrogate biomarker |
| الوصف: | INTRODUCTION: Increasing evidence suggests that amyloid reduction could serve as a plausible surrogate endpoint for clinical and cognitive efficacy. The double-blind phase 3 DIAN-TU-001 trial tested clinical and cognitive declines with increasing doses of solanezumab or gantenerumab. METHODS: We used latent class (LC) analysis on data from the Dominantly Inherited Alzheimer Network Trials Unit 001 trial to test amyloid positron emission tomography (PET) reduction as a potential surrogate biomarker. RESULTS: LC analysis categorized participants into three classes: amyloid no change, amyloid reduction, and amyloid growth, based on longitudinal amyloid Pittsburgh compound B PET standardized uptake value ratio data. The amyloid-no-change class was at an earlier disease stage for amyloid amounts and dementia. Despite similar baseline characteristics, the amyloid-reduction class exhibited reductions in the annual decline rates compared to the amyloid-growth class across multiple biomarker, clinical, and cognitive outcomes. DISCUSSION: LC analysis indicates that amyloid reduction is associated with improved clinical outcomes and supports its use as a surrogate biomarker in clinical trials. Highlights: We used latent class (LC) analysis to test amyloid reduction as a surrogate biomarker. Despite similar baseline characteristics, the amyloid-reduction class exhibited remarkably better outcomes compared to the amyloid-growth class across multiple measures. LC analysis proves valuable in testing amyloid reduction as a surrogate biomarker in clinical trials lacking significant treatment effects. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://discovery.ucl.ac.uk/id/eprint/10189432/1/Examining%20amyloid%20reduction%20as%20a%20surrogate%20endpoint%20through%20latent%20class%20analysis.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10189432Test/ |
| الإتاحة: | https://discovery.ucl.ac.uk/id/eprint/10189432/1/Examining%20amyloid%20reduction%20as%20a%20surrogate%20endpoint%20through%20latent%20class%20analysis.pdfTest https://discovery.ucl.ac.uk/id/eprint/10189432Test/ |
| حقوق: | open |
| رقم الانضمام: | edsbas.1AD3FA76 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |